Viva Biotech Holdings

Viva Biotech Holdings, founded in 2008 and based in Shanghai, China, operates as an investment holding company primarily dedicated to providing comprehensive, structure-based drug discovery services to biotechnology and pharmaceutical clients worldwide. Its extensive discovery biology offerings encompass protein expression and purification, structural biology, hit identification, bioassay development, biomolecular interaction analysis, and pharmacokinetic studies. The company also delivers a suite of chemistry services, including medicinal and synthetic chemistry, analytical services, preparative purification, and computer-aided drug design, all supported by robust chemical technology platforms. Viva Biotech further specializes in antibody drug research and development, covering antigen preparation, multi-species antibody discovery, monoclonal antibody production, functional screening and characterization, antibody engineering, and cell line engineering. This work is facilitated by cutting-edge technological platforms such as hybridoma, phage and yeast display, mammalian display, VHH antibody technology, high-throughput sequencing, computer-aided drug design, HDX-MS, protein crystal structure determination, and SPR technology. Beyond its core service offerings, Viva Biotech provides various biological resources, including cell lines, crystal structures, GPCR proteins, antibodies, and other purified proteins. The company also offers contract development and manufacturing (CDMO) services for small molecule active pharmaceutical ingredients (APIs) and their intermediates. Furthermore, it engages in the trading of APIs, intermediates, and formulations, and operates under an "equity for service" model. Additional services include general research, laboratory facility rentals, project management and bidding assistance, and the sale of chemical compounds.

產業

Biotechnology

部門

Healthcare

總部

CN

執行長

Chen Cheney Mao

上市以來

2019年5月9日

僱員

2,169